^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    STK11 mutation

    i
    Other names: Serine/Threonine-Protein Kinase 11, Liver Kinase B1, Serine/Threonine-Protein Kinase LKB1, Polarization-Related Protein LKB1, STK11, Serine/Threonine Kinase 11, Serine/Threonine-Protein Kinase STK11, Renal Carcinoma Antigen NY-REN-19
    Entrez ID:
    6794
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    9ms
    Choose your player! Drs. @SusanScottMD and @Joshua_Reuss will face off at #DCLung23 on whether STK11/KEAP1 mutations should influence 1L NSCLC treatment. Visit us in downtown DC on Saturday, October 7, 2023 to vote! Full agenda registration at: https://t.co/rJa81GX23a (@StephenVLiu)
    STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    STK11 mutation • KEAP1 mutation
    11ms
    #ASCO23 @ASCO Presenting on real world outcomes of 1L ICI in KRASG12C MT #NSCLC ➡️ Pts with KRASMT TPS<1 have worse OS! ➡️ Co-mutations w/ STK11/ KEAP assoc with worse OS ⁦@OncoAlert⁩ ⁦@TempusLabs⁩ ⁦@JPatelMD⁩ (@CharuAggarwalMD)
    Clinical • Real-world evidence • Real-world
    |
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)
    |
    KRAS G12C • STK11 mutation • KRAS G12
    11ms
    Excellent merit award work from Dr. @Sam_Rosner_ in our collaboration with @DoctorJSpicer &. @JonesDavid2013 @ChaftJamie . Small numbers but oncogenic mutations incl STK11 may play a role in response to neoadjuvant IO, watch this space! #LCSM https://t.co/mFqtZFJZqI (@FordePatrick)
    Clinical
    |
    STK11 (Serine/threonine kinase 11)
    |
    STK11 mutation
    12ms
    5/8 In examining clinical outcomes to PD-(L)1 based therapies, there was no difference between patients with ATM mutant and ATM wild-type NSCLC, despite increased TMB/PD-L1 expression (though higher rate of KRAS/STK11 co-mutations) in the ATM mutant subset. (@BiagioMd)
    Clinical • Clinical data • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ATM (ATM serine/threonine kinase) • STK11 (Serine/threonine kinase 11)
    |
    PD-L1 expression • KRAS mutation • PD-L1 overexpression • ATM mutation • STK11 mutation • ATM expression • KRAS expression
    12ms
    2/8 We identified 562 deleterious ATM mutations in 9.7% (503/5172) of NSCLC samples. ATM mutations were associated with high TMB, increased PD-L1 expression and were enriched in KRAS, STK11, and ARID2 co-mutations. TP53 and EGFR mutations were enriched in ATM wild-type NSCLCs. (@BiagioMd)
    IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • ATM (ATM serine/threonine kinase) • STK11 (Serine/threonine kinase 11) • ARID2 (AT-Rich Interaction Domain 2)
    |
    PD-L1 expression • TP53 mutation • KRAS mutation • EGFR mutation • TMB-H • ATM mutation • STK11 mutation • KRAS mutation + STK11 mutation + TP53 mutation • KRAS expression
    12ms
    Now @JCO_ASCO: 2-year analysis of sotorasib in 174 pts with #KRAS G12C NSCLC from CodeBreaK 100. RR 41%, mDOR 12.3m, mPFS 6.3m, mOS 12.5m, 2y OS rate 33%, 23% with PFS ≥1y. Long term benefit just as likely with or without STK11 comutation. https://t.co/4lK27cP9G3 (@StephenVLiu)
    Clinical
    |
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)
    |
    KRAS G12C • STK11 mutation • KRAS G12
    |
    Lumakras (sotorasib)
    1year
    Fantastic real-world collaboration led by @FSkoulidis: KEAP1, SMARCA4, and CDKN2A mutations contribute to roughly 50% of early progression in KRAS G12C targeted treated #NSCLC. TP53 and STK11 comutations without impact. Happy to be on board. #LCSM @KRASKickers (@trnsltnl)
    Clinical • Real-world evidence • Real-world
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • KEAP1 (Kelch Like ECH Associated Protein 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
    |
    TP53 mutation • KRAS G12C • STK11 mutation • KEAP1 mutation • CDKN2A mutation • KRAS G12 • SMARCA4 mutation
    1year
    Dr. @HosseinBorghaei discusses dual checkpoint blockade for advanced NSCLC at #TexasLung23. Appeal is durability but what is the right biomarker? Is it STK11/KEAP mutations? Great lead-in to debate tomorrow between @benlevylungdoc and @DrSteveMartin! @TLCconference (@StephenVLiu)
    Checkpoint inhibition • Checkpoint block • Metastases
    |
    STK11 (Serine/threonine kinase 11)
    |
    STK11 mutation
    1year
    Retrospective report @ClinicalLung on real world outcomes in pts with #KRAS G12C NSCLC from #ATOMIC consortium. First-line rwPFS 9.3m and 2nd line rwPFS with docetaxel-based therapy 4.6m. Outcomes worse with STK11 co-mutation. https://t.co/Swrqqb29oN (@StephenVLiu)
    Retrospective data • Real-world evidence • Real-world
    |
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)
    |
    KRAS G12C • STK11 mutation • KRAS G12
    |
    docetaxel
    1year
    Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus CT Versus CT For Metastatic NSCLC. @JTOonline 👉🏻 https://t.co/qtY0xNhoW0 #nsclc #lcsm #tmb #mutationstatus #kras #stk11 #immunotherapy #IO+Chemo (@diegoadiazg)
    Clinical • Clinical data • Tumor mutational burden • IO biomarker • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden) • STK11 (Serine/threonine kinase 11)
    |
    KRAS mutation • STK11 mutation
    |
    Keytruda (pembrolizumab)
    over1year
    Great work! So now investigators have reported KRAS, KEAP1, and STK11 mutations as poor prognosticators in early-stage NSCLC treated with SBRT. We will have to figure out how co-mutations actually affect outcomes! #radonc #lcsm (@HenningWillers)
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    STK11 mutation • KEAP1 mutation • STK11 mutation + KEAP1 mutation
    over1year
    https://t.co/jix7DORqqW Pancancer #KRAS mutations survey and survival outcome and by TP53, STK11,KEAP1, NFE2L2 by @foundationATCG. 24 months to prepare.#LCSM (@oncoOuLungCA)
    Pan tumor
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    TP53 mutation • KRAS mutation • STK11 mutation
    over1year
    Update from POSEIDON (1L durvalumab + tremelimumab + chemotherapy) for NSCLC by Dr. Byoung Chul Cho at #ESMOAsia22. Median f/u 46m and OS benefit seen with addition of durva + treme persists (OS HR 0.75 vs chemo) including in STK11 mutant non-squamous subset. (@StephenVLiu)
    STK11 (Serine/threonine kinase 11)
    |
    STK11 mutation
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab)
    over1year
    Excited to share #RWD to examine outcomes to ICI vs ICI+CTx in NSCLC with KRAS, STK11, KEAP1 mutations #SITC2022. This is a heterogenous group & requires a tailored approach. This data has implications not only for treatment selection but also for trial design #LCSM (@JPatelMD)
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    KRAS mutation • STK11 mutation • KEAP1 mutation
    over1year
    A #STING operation to expose #KRAS and #STK11 co-mutated lung cancers: #Cancer ⁦@TheMarkFdn⁩ https://t.co/ChC1iOfrKG (@Rndubois)
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • STING (stimulator of interferon response cGAMP interactor 1)
    |
    KRAS mutation • STK11 mutation
    over1year
    $TNGX disclosed today the target of their third candidate, TNG260, a CoREST deacetylase inhibitor to reverse immune evasion in STK11-mutant cancers (15% of NSCLC). Multiple related poster presentations coming at #SITC22. IND filing expected in 1H23. (@blackseedbio)
    STK11 (Serine/threonine kinase 11)
    |
    STK11 mutation
    |
    TNG260
    over1year
    Thanks for sharing. Stk11 loss or mutation ~8% of NSCLC and 6% are either Ras or Keap1 co-mutated. That leaves 2% that are not. If you add EGFR, Alk, rare fusions, the piece of the pie that ICI may impact gets smaller. Let's sequence and analyze as we enroll so we can tailor. (@theabzlab)
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1) • RAS (Rat Sarcoma Virus)
    |
    EGFR mutation • STK11 mutation • KEAP1 mutation
    over1year
    2/ Jiyeon studied an aggressive #lungcancer subset with mutations in KRAS and STK11/LKB1 (KL). Both genes regulate metabolism, so Jiyeon reasoned that unusual liabilities would emerge when both were mutated together. There was precedent for this idea from Kwok-Kin Wong and others (@RJDLab)
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)
    |
    KRAS mutation • STK11 mutation
    over1year
    #TumorBoardTuesday Yeah - not the best English 🤣 What I meant to convey about germline STK11 mutations was: - There is a risk of colon, pancreatic, stomach, and breast cancer - There is a risk of lung cancer too - even in non-smokers (@MPishvaian)
    STK11 (Serine/threonine kinase 11)
    |
    STK11 mutation
    over1year
    #TumorBoardTuesday Just to be clear - in NSCLC, we are referring to SOMATIC mutations in STK11 But, while not the most common cancer associated, there is a risk for #NSCLC in patients who harbor germline STK11 mutations too @HHampel1 @anu_iris @PancPathologist (@MPishvaian)
    Clinical
    |
    STK11 (Serine/threonine kinase 11)
    |
    STK11 mutation
    over1year
    Dr. Giuseppe Lamberti @GLambertiMD @DanaFarber presents clinicogenomic factors in 92 patients with KRAS G12C mutant NSCLC tx with Sotorasib or Adagrasib: STK11 and CDKN2A Mut/loss impact PFS, ECOG PS 2 or higher had detrimental effect on OS @DrMarkAwad. (@GRecondoMD)
    Clinical
    |
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12
    |
    Lumakras (sotorasib) • Krazati (adagrasib)
    over1year
    🧵9 We identify recurrent #STK11 mutations in SCLC, which are enriched in patients of AFR ancestry. ➡️Pts with STK11 mutations have poorer overall survival compared with the STK11 WT cohort. ➡️Possible implications for immunotherapy treatment? (@christine_lovly)
    Clinical • IO biomarker
    |
    STK11 (Serine/threonine kinase 11)
    |
    STK11 mutation
    almost2years
    🚨Insightful piece on the emerging importance of tumor co-mutations in #lungcancer 🚨 Seems like free full text🙏 @SalmaJabbour1 #lcsm 📢Clinical outcomes and immune phenotypes associated with STK11 co-occurring mutations in non-small cell lung cancer https://t.co/5RmomCRfZZ (@HenningWillers)
    Clinical • Clinical data
    |
    STK11 (Serine/threonine kinase 11)
    |
    STK11 mutation
    almost2years
    Congrats and thanks ⁦@AndresFCardonaZ⁩ for leading this ⁦@CLICaP_⁩ effort STK11 and KEAP1 mutations in non-small cell lung cancer patients: descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP) ⁦@lcsmchat⁩ https://t.co/uGneIU71hS (@ChristianRolfo)
    Clinical
    |
    STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    STK11 mutation • KEAP1 mutation
    almost2years
    our @CLICaP_ paper about STK11 and KEAP1 mutations in #lungcancer #Immunotherapy is in the journal Lung Cancer! these mutations are associated with inferior OS in Hispanics @ogarrieta @AndresFCardonaZ @ChristianRolfo @lucia_zatarain @DrClaudiomartin @UmbertoMalapel1 #LCSM (@LuisERaez1)
    IO biomarker
    |
    STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    STK11 mutation • KEAP1 mutation
    almost2years
    A new CLICaP publication will appear shortly in Lung Cancer. An interesting study to characterize the prognostic role of STK11/KEAP1 mutations in Hispanic patients with NSCLC! (@AndresFCardonaZ)
    Clinical
    |
    STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    STK11 mutation • KEAP1 mutation
    almost2years
    Fantastic work by @BiagioMd @DrMarkAwad @GRecondoMD @alessi_joao @FordePatrick and they raise a very important point, integrated biomarkers is the way of the future, but we will have to factor in co-mutation status including STK11, KRAS etc #LCSM (@CharuAggarwalMD)
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)
    |
    KRAS mutation • STK11 mutation
    2years
    Great work from @BiagioMd & @DrMarkAwad @DanaFarber on ATM expression in NSCLC. ATM mutations associated seem to be associated with females, tobacco exp, & KRAS/STK11 mutation. ATM status likely predictor of response to DDR agents #AACR22 #LCSM (@LUNGevity)
    KRAS (KRAS proto-oncogene GTPase) • ATM (ATM serine/threonine kinase) • STK11 (Serine/threonine kinase 11)
    |
    KRAS mutation • ATM mutation • STK11 mutation • ATM expression
    2years
    Amazing to see #AI impact on #pathology: deep-learning models can assist pathologists in the detection of NSCLC subtypes & specific gene #mutations (STK11, EGFR, FAT1, SETBP1, KRAS & TP53). https://t.co/iTYsaQX31Y (@jsoriamd)
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • FAT1 (FAT atypical cadherin 1) • SETBP1 (SET Binding Protein 1)
    |
    TP53 mutation • KRAS mutation • EGFR mutation • STK11 mutation
    2years
    Glad to had the opportunity to share pur work on KRAS G12C-STK11 co-mutated lung adenocarcinoma during #USCAP2022 (@RaduPirlogMD)
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • SKAP2 (Src Kinase Associated Phosphoprotein 2)
    |
    KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12 • KRAS G12C + STK11 mutation
    2years
    Important to look at the mutational context of #KRAS mutations in NSCLC. Dr. @SukiPaddaMD shows how co-mutations in STK11 are associated with outcome and illustrates how co-mutation with KEAP1 further stratifies. Co-mutations drive biology and likely to drive treatment #TTLC22 (@StephenVLiu)
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    KRAS mutation • STK11 mutation • KEAP1 mutation
    2years
    Dr. Liza Villarus walked us through IO combinations with small molecule inhibitors esp PARPi and ATRi- lots of trials in this space, but nothing striking, so far, but maybe there is a signal in STK11 Mutant NSCLC? #TTLC22 @IASLC #LCSM (@CharuAggarwalMD)
    STK11 (Serine/threonine kinase 11)
    |
    STK11 mutation
    2years
    New #JITC article: Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial https://t.co/Im9VJ0DcoY @JackWestMD (@jitcancer)
    Clinical
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    TP53 mutation • KRAS mutation • STK11 mutation • KEAP1 mutation
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    over2years
    🆕@CD_AACR Functional STK11 mutations is associated with resistance to ICIs in #lungcancer & is reversed by STAT3 knockdown 🌟 #LCSM https://t.co/vKnWE5toDW (@APassaroMD)
    STK11 (Serine/threonine kinase 11) • STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    STK11 mutation
    over2years
    #ccabestofoncology @CharuAggarwalMD noting that NSCLC patients with KRAS G12C have variable ORR sotorasib by co-occurring mutations in STK11 and KEAP1. Lower response rate 23%ORR if both mutated, higher ORR of 50% with mutant STK11 and wild type KEAP1. #gcchat #asco21 (@Karen_GC_Cincin)
    Clinical
    |
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    KRAS G12C • STK11 mutation • KEAP1 mutation • KRAS G12
    |
    Lumakras (sotorasib)
    over2years
    As Dr. Naqash discusses, STK11 and TP53 mutated NSCLC, has a unique immune TME compared to STK11mut/TP53 wild-type or STK11/KRAS mutated. Co-mutations matter! (@PaulRWalker4)
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11)
    |
    TP53 mutation • KRAS mutation • STK11 mutation
    almost3years
    #ASCO21 Benefit seen across co-mutations in TP53 and STK11 (seems lower in KEAP1 mutant). Subgroup of STK11 mutant with KEAP1 wild type had better outcomes (mPFS 11m) but the numbers here are quite small and exploratory. #LCSM (@StephenVLiu)
    TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    TP53 mutation • STK11 mutation • KEAP1 mutation
    almost3years
    (2/4) @KCArbourMD identified 770 patients with KRAS mutant metastatic NSCLC. 46% had KRAS G12C. Patients with KRAS G12C had higher TMB and higher PD-L1 compared with other KRAS mutations. Overlap of STK11/KEAP1 were same in KRAS G12C/non-G12C. https://t.co/RWeF1GDWHg (@RielyMD)
    Clinical • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    KRAS mutation • TMB-H • KRAS G12C • STK11 mutation • KRAS G12
    almost3years
    Nice reminder. I got a NSCLC pt this wk who got KRAS G12C, STK11 & KEAP1 mutations. Wait... there is more. He has ESRD on peritoneal dialysis. And some years ago he survived a massive MI w/ ventricular rupture !!? (the CT surgeon fixed it 💖😅👍🙏😇🥂). Lung ca not mean much now. (@PatrickCMa1)
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    KRAS G12C • STK11 mutation • KEAP1 mutation • KRAS G12
    3years
    .@mylovelypinata highlights previous failures in drugging KRAS pathway in #NSCLC either downstream or with synthetic lethality . Major optimism with direct G12C inhibitors: "momentous results" Active in STK11/KEAP1 mutants #BTOG21 (@DrSanjayPopat)
    Synthetic lethality
    |
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    KRAS G12C • STK11 mutation • KEAP1 mutation
    3years
    We knew that adagrasib is efficient in KRAS G12C mut #NSCLC Interestingly the north face of lung cancer (KRAS and STK11 comutations) can be surmounted by this drug. @OncoAlert #ELCC21 @RielyMD (@JulienMazieres)
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)
    |
    KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12
    |
    Krazati (adagrasib)
    3years
    #ELCC21 High RR in STK11 mutant NSCLC noted and intriguing data showing adagrasib increased activation of IFN signaling. Does this support concurrent or sequential use of adagrasib with checkpoint inhibition? Need to see data (esp safety) from other combo cohorts. #LCSM (@StephenVLiu)
    Clinical • Checkpoint inhibition
    |
    STK11 (Serine/threonine kinase 11)
    |
    STK11 mutation
    |
    Krazati (adagrasib)